Cortexyme, Inc. (CRTX)
Stock Price:
$45.75 USD
-0.05 (-0.11%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.35B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-48.48M |
| Shares Out |
29.42M |
| EPS (ttm) |
-1.92 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$45.75 |
| Previous Close |
$45.80 |
| Change ($) |
-0.05 |
| Change (%) |
-0.11% |
| Day's Open |
45.93 |
| Day's Range |
45.12 - 46.93 |
| Day's Volume |
163,812 |
| 52-Week Range |
19.35 - 73.84 |
More Stats
| Market Cap |
1.35B |
| Enterprise Value |
1.18B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
29.42M |
| Float |
13.11M |
| EPS (basic) |
-1.9 |
| EPS (diluted) |
-1.92 |
| FCF / Share |
-1.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.68M |
| Short Ratio |
6.29 |
| Short % of Float |
9.81% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.37 |
| Revenue |
n/a |
| Operating Income |
-50.95M |
| Net Income |
-48.48M |
| Free Cash Flow |
-33.34M |
| Net Cash |
162.36M |
| Net Cash / Share |
5.52 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-21.10% |
| ROE |
-34.12% |
| ROIC |
-52.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$61.33*
(34.05% upside)
Low
14.0
Current: 45.75
High
84.0
Target: 61.33
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -39.17 | -12.12 | -10.37 |
| Net Income | -36.98 | -12.48 | -12.24 |
| Shares Outstanding | 19.03 | 3.36 | 3.30 |
| Earnings Per Share | -1.94 | -3.71 | -3.70 |
| Operating Cash Flow | -33.28 | -11.70 | -9.83 |
| Capital Expenditures | -0.06 | -0.21 | -0.08 |
| Free Cash Flow | -33.33 | -11.91 | -9.90 |
| Cash & Equivalents | 99.86 | 71.72 | 7.39 |
| Total Debt | - | - | 7.17 |
| Net Cash / Debt | 99.86 | 71.72 | 0.22 |
| Assets | 124 | 72.88 | 7.72 |
| Liabilities | 8.89 | 1.46 | 10.82 |
| Book Value | 115 | -32.63 | -20.28 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cortexyme, Inc. |
| Country |
United States |
| Employees |
23 |
| CEO |
Casey Crawford Lynch |
Stock Information
| Ticker Symbol |
CRTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CRTX |
Description
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.